The Global NASH/MASH Council (GNC) and the Global Liver Council (GLC) are pleased to announce that 21 abstracts from our collaborative research programs have been accepted for presentation at The Liver Meeting 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place this November in Denver, Colorado.
The accepted work includes:
4 Oral Presentations
4 Posters of Distinction
13 Posters
Together these studies span the epidemiology, diagnosis, treatment, patient-reported outcomes, and economic burden of steatotic liver disease, viral hepatitis, and liver transplantation across global populations.
What unites this body of work is its scale and its reach. The GNC and GLC were established on the conviction that liver disease is a global problem that cannot be understood, much less solved, from any single country or health system. The abstracts presented here reflect that conviction in practice: multinational surveys of clinical practice spanning dozens of countries across six continents, pooled registry and cohort analyses linking data from North America, Europe, Latin America, the Middle East, Africa, and the Asia-Pacific region, and global genetic and biomarker studies made possible only by investigators willing to contribute data and expertise to a shared effort.
These collaborations bring together hepatologists, epidemiologists, methodologists, health economists, and patient-outcomes researchers from academic centers, public health institutions, and clinical practices worldwide. By pairing that breadth with consistent methodology, our councils are able to produce evidence that is genuinely generalizable, that captures the disparities and regional differences too often lost in single-country studies, and that can inform policy and clinical guidance in the very settings where the burden of liver disease is growing fastest. We congratulate and thank all of our collaborating members, and partners around the world, whose sustained commitment made this collective achievement possible.
Accepted Abstracts
1. Sex-Specific Epidemiology and Outcomes in Chronic Liver Disease: A 20-Year US Registry Analysis of Liver Transplant Candidates and Recipients
Authors: Linda Henry1, Maria Stepanova1, Giacomo Germani1,2, Adrian Gadano1,3, Patrizia Burra1,2, Rohit Satoskar1,4, Khalid M. AlNaamani1,5, Saleh A. Alqahtani1,6,7, Zobair M. Younossi1,8,9
Type of Presentation: Oral Presentation
2. Sequential Algorithms Using FIB-4, Followed by VCTE or ELF to Detect Advanced Fibrosis: Validation of Risk Stratification Strategy in the United States (U.S.) Primary Care Setting
Authors: Zobair M. Younossi MD1,2, James M. Paik PhD1,2, Leyla de Avila BS1, Maria Stepanova PhD1, Markos Kalligeros MD1, 3, Annette Paik1, Khalid M. Al Naamani MD1,4, Saleh AlQahtani MD1,5, Linda Henry PhD1,6
Type of Presentation: Oral Presentation
3. Beyond Alcohol Self-Report: Phosphatidylethanol (PEth) Assessment Uncovers Clinically Significant Alcohol Exposure in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Authors: Zobair M. Younossi¹˒² *, Nikolaj Torp¹˒³ *, Fatema Nader¹, Mads Israelsen¹˒³, Camilla Dalby Hansen³, Markos Kelligerous¹˒⁴, Johanne Kragh Hansen¹, Linda Henry¹˒⁶, Helle Schnefeld¹, Andrei Racila¹˒⁵, Katrine Tholstrup Bech¹, Shira Zelber-Sagi¹˒⁵, Marianne Lerbaek Bergmann¹,7, Maria Stepanova¹˒⁶ ⁺, Aleksander Krag¹˒³ ⁺
Type of Presentation: Oral Presentation
4. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Outpacing Alcohol-Associated Liver Disease (ALD) as the Principal Driver of Rising Steatotic Liver Disease-Associated Liver Cancer
Authors: Eliabe S. Abreu 1,2 , James M. Paik 1,3 , Manal Abdelmalek 1,2 , Robert Wong 1,4 , Khalid M. Al Naamani 1,5 ,Saleh Alqahtani 1,6 , Zobair M. Younossi 1,3,7
Type of Presentation: Oral Presentation
5. Reallocating Sedentary Time to Sleep Is Associated With Improved Disease Severity in MASLD
Authors: Lynn H. Gerber1*, James M. Paik1,2*, Markos Kalligeros 1, Shelley E Keating 1, 3, Ali A. Weinstein, 1, 4, Jonathan G Stine 5, Shira Zelber-Sagi1, Saleh Alqahtani1,6,7, Kate Hallsworth, 1,8, Elizabeth J. Pekas 1, Zobair M. Younoss1,2
Type of Presentation: Poster of Distinction
6. Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire (CLDQ-MASH-SQ)
Authors: Zobair. M Younossi 1,2, Maria Stepanova 1, Issah Younossi 2, Andrei Racila 1
Type of Presentation: Poster of Distinction
7. Genetic polymorphisms associated with metabolic dysfunction–associated steatotic liver disease (MASLD) and adverse clinical outcomes: a global study
Authors: Zobair M. Younossi¹˒², Leyla de Avila BS¹˒², Khalid N. AlNaamani¹˒³, Cristiane Villela-Nogueira¹˒⁴, Luca Valenti¹˒⁵, Phunchai Charatcharoenwitthaya¹˒⁶, Javier Crespo¹˒⁷, Silvia Sookoian¹˒⁸, Vincent Wai-Sun Wong¹˒⁹, Atsushi Nakajima¹˒¹⁰, Yusuf Yilmaz¹˒¹¹, Claudia de Oliveira¹˒¹², Mario G. Pessoa¹˒¹², Anna Fracanzani¹˒¹³, Rosa Lombardi¹˒¹³, Wah Kheong Chan¹˒¹⁴, Adriaan G. Holleboom¹˒¹⁵, Jian-Gao Fan¹˒¹⁶, Andrea Siciliano⁵, Giulia Periti⁵, Francesco Malvestiti⁵, Watcharin Wichapolchaiyakul⁶, Paula Izrubieta⁷, Carlos J. Pirola⁸, Takashi Kobayashi¹⁰, Shamsul Mohd Zain17, Kirsi van Eekhout¹⁵, Rui-Xu Yang¹⁶, J. Michael Estep¹, Brian Lam PA¹, Andrei Racila¹, Saleh A. Alqahtani 1, 18, Maria Stepanova PhD¹˒19, on behalf of the Global NASH/MASH Council (GNC)
Type of Presentation: Poster of Distinction
8. Liver Transplantation for Alcohol-Related Hepatitis Versus Alcohol-Related Cirrhosis in the United States from 2000–2025: Disease Severity and Clinical Outcomes
Authors: Maria Stepanova1, Giacomo Germani1,2, Adrian Gadano1,3, Patrizia Burra1,2, Rohit Satoskar1,4, Linda Henry1, Saleh A. Alqahtani1,5,6, Zobair M. Younossi1,7,8
Type of Presentation: Poster of Distinction
9. Impact of Resmetirom on Health-Related Quality of Life, Work Productivity, and Disease-Specific Symptoms in Compensated MASH Cirrhosis
Authors: Zobair M. Younossi1, Fatema Nader1, Becky Taub3, Andrei Racila1,3, Maria Stepanova1,3
Type of Presentation: Poster
10. The Development Divide: How Food Systems Drive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Different Structural Pathways Across 204 Countries
Authors: James M. Paik1, 2, Markos Kalligeros1, 3, Shira Zelber-Sagi1, 4, Annette Paik1, Saleh A. Alqahtani 1, 5, Zobair M. Younossi1, 2, 6
Type of Presentation: Poster
11. Factors affecting the management of immunotolerant chronic HBV patients: Results from a worldwide survey of clinical practice
Authors: George Papatheodoridis1,2, Maria Buti1,3, Margarita Papatheodoridi, Phunchai Charatcharoenwitthaya1,4, Ajeet Bhadoria1,5, Jian-Gao Fan1,6, Brian Pearlman1,7, Cristiane Villela-Nogueira1,28, Shivaram Prasad Singh1,9, Satoru Kakizaki1,10, Wah-Kheong Chan1,11, Anand Kulkarni1,12, Ashwani K. Singal1,13, Ana Ostojić1,14, Javier Crespo1,15, Christian Tzeuton1,16, Jimmy Che-To Lai1,17, Loreta Kondili1,18, Munkhbat Batmunkh1,19, Munkhjargal Ayurzana1,20, Ming-Lung Yu1,21, George Boon Bee Goh1,22, Dimitrios S. Karagiannakis1,23, Ellina Lytvyak1,24, Amit Goel1,25, Al Naamani Khalid1,26, C Wendy Spearman1,27, Ira Jacobson1,28, Tatyana Kushner1,29,Davaadorj Duger1,20, Yuichiro Eguchi1,30, Mohamed El-Kassas1,31, Sarantuya Gidaagaya1,20, Stuart C Gordon1,32, Saira Khaderi1,33, Pietro Lampertico1,34, Mei‑Ηsuan Lee1,35, Bira Namdag1,20, Ponsiano Ocama1,36, Mario Pessoa1,37, Nikolaos T. Pyrsopoulos1,28, Francesco Paolo Russo1,38, Yusuf Yilmaz1,39,Linda Henry1, Fatema Nader1, Andrei Racila Jr1, Maria Stepanova1, Janus Ong1,40, Zobair Younossi1,41,42
Type of Presentation: Poster
12. Practice patterns and determinants of hepatocellular carcinoma (HCC) surveillance in patients with chronic hepatitis B virus (HBV) infection: Results from a worldwide survey of clinical practice
Authors: George Papatheodoridis1,2, Maria Buti1,3, Margarita Papatheodoridi, Phunchai Charatcharoenwitthaya1,4, Ajeet Bhadoria1,5, Jian-Gao Fan1,6, Brian Pearlman1,7, Cristiane Villela-Nogueira1,28, Shivaram Prasad Singh1,9, Satoru Kakizaki1,10, Wah-Kheong Chan1,11, Anand Kulkarni1,12, Ashwani K. Singal1,13, Ana Ostojić1,14, Javier Crespo1,15, Christian Tzeuton1,16, Jimmy Che-To Lai1,17, Loreta Kondili1,18, Munkhbat Batmunkh1,19, Munkhjargal Ayurzana1,20, Ming-Lung Yu1,21, George Boon Bee Goh1,22, Dimitrios S. Karagiannakis1,23, Ellina Lytvyak1,24, Amit Goel1,25, Al Naamani Khalid1,26, C Wendy Spearman1,27, Ira Jacobson1,28, Tatyana Kushner1,29,Davaadorj Duger1,20, Yuichiro Eguchi1,30, Mohamed El-Kassas1,31, Sarantuya Gidaagaya1,20, Stuart C Gordon1,32, Saira Khaderi1,33, Pietro Lampertico1,34, Mei‑Ηsuan Lee1,35, Bira Namdag1,20, Ponsiano Ocama1,36, Mario Pessoa1,37, Nikolaos T. Pyrsopoulos1,28, Francesco Paolo Russo1,38, Yusuf Yilmaz1,39,Linda Henry1, Fatema Nader1, Andrei Racila Jr1, Maria Stepanova1, Janus Ong1,40, Zobair Younossi1,41,42
Type of Presentation: Poster
13. Cost-Effectiveness of Sequential Non-Invasive Testing (NIT) for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Risk Stratification in US Primary Care: A Lifetime Markov Analysis
Authors: Zobair M. Younossi1,2, Khalid AlNaamani¹˒³, Cristiane Villela-Nogueira¹˒⁴, Fatema Nader1, Saleh A. Alqahtani 1,5, Laurent Castera1,6,*,James M. Paik1,2,7,*
Type of Presentation: Poster
14. Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Type 2 Diabetes (T2D) Across Nine Countries: Economic Burden and Real-World Implementation Impact (2025–2045)
Authors: Zobair M. Younossi1,2, Frank Tacke1,3, Patrizia Burra1,4, Cristiane A. Villela-Nogueira1,5, Javier Crespo1,6, Elisabetta Bugianesi1,7, Hirokazu Takahashi1,8, Yuichiro Eguchi1,9, Mário Guimarães Pessoa1,10, Claudia Pinto Oliveira1,10, Michael Roden1,11, Cyrielle Caussy1,12, Amalia Gastaldelli13, Fernando Bril1,14, Jeremy W. Tomlinson1,15, Paul N. Brennan1,16, Manuel Romero-Gomez1,17, Takumi Kawaguchi1,18, Jerome Boursier1,19, Faisal Abaalkhail1,20, Ahmed Al-Jedai21, Hussain Abdulrahman Al-Omar1,22, Maria Stepanova1, Fatema Nader1, Markos Kalligeros1,23, Laurent Castera1,24, Saleh A. Alqahtani1,25*, James M. Paik1,2,26*
Type of Presentation: Poster
15. Two-Decade Trends and Outcomes of Liver Transplantation for Autoimmune Hepatitis in the United States and Europe
Authors: Maria Stepanova1, Giacomo Germani1,2, Ana Lleo1,3, Vincent Karam4, Rene Adam5, Saleh A. Alqahtani1,6,7, Linda Henry1,2,8, Patrizia Burra1,2, Zobair M. Younossi1,8,9
Type of Presentation: Poster
16. Liver Transplantation for Steatotic Liver Disease in the United States: Trends and Outcomes from 2000–2025
Authors: Zobair M. Younossi1,2 , Giacomo Germani1,3, Adrian Gadano1,4, Patrizia Burra1,3, Linda Henry1, Khalid M. AlNaamnai1,5, Saleh A. Alqahtani1,6,7, Maria Stepanova1
Type of Presentation: Poster
17. Steatotic Liver Disease (SLD) Subtypes Among Adolescents in the United States: A Nationally Representative Study
Authors: Zobair M. Younossi1,2, Annette Paik1, Fatema Nader1,3, Andrei Racila1,3, James M. Paik1,2
Type of Presentation: Poster
18. Racial and Ethnic Disparities in Steatotic Liver Disease (SLD) Subtypes Using a Novel Alcohol-Corrected Classification
Authors: Zobair M. Younoss1,2, Markos Kalligeros1, 3, Annett Paik1, Khalid Al Naamani1,4, Waleed Alhazzani1,5, Shadan AlMuhaidib1,5, Basmah Khoja1,6, Saleh AlQahtani1,6, James M. Paik1,2,7
Type of Presentation: Poster
19. Treatment with Resmetirom Improves Symptom Burden in Metabolic Dysfunction-Associated Steatohepatitis
Authors: Zobair M. Younossi1, Fatema Nader1, Becky Taub3, Andrei Racila1,3, Maria Stepanova1,3
Type of Presentation: Poster
20. Health-related quality of life in MASLD/MASH treated with essential phospholipids shows improvement in fatigue and activity: CLDQ-MASH results from the EXCEL randomized trial
Authors: Zobair M.Younossi, MD; Maria Stepanova, PhD; Katarzyna Wielgus; Branko khalid
Popovic
Type of Presentation: Poster
21. Faster national development amplifies MASLD but not viral hepatitis or alcohol-associated liver disease
Authors: James M. Paik1,2, Eliabe S. Abreu1,3, Annette Paik1, Khalid Al Naamani1,4, Mohamed El-Kassas1,5, Cristiane Villela-Nogueira1,6˒, Saleh AlQahtani1,7, Zobair M. Younossi1,2,8
Type of Presentation: Poster
